STF 62247,
STF-62247,
STF62247,
STF-62247,
315702-99-9,
Autophagy Inducer, STF-62247,
4-(pyridin-4-yl)-N-(m-tolyl)thiazol-2-amine,
N-(3-methylphenyl)-4-pyridin-4-yl-1,3-thiazol-2-amine,
STF62247,
N-(3-methylphenyl)-4-(pyridin-4-yl)-1,3-thiazol-2-amine,
SMR000279642,
SR-01000477178,
BAS 00679420,
AC1LE0OH,
4-(pyridin-4-yl)-N-m-tolylthiazol-2-amine,
Oprea1_055220,
Oprea1_578909,
MLS000765936,
MLS006011714,
SCHEMBL996232,
CHEMBL565269,
CTK8E7436,
ZINC88369,
DTXSID90351598,
CHEBI:125656,
KATNUHQNJGNLPW-UHFFFAOYSA-N,
HMS2667I13,
HMS3648C10,
HMS3654K09,
EX-A2421,
KS-00000L0A,
2732AH,
ABP000372,
CCG-19235,
s1041,
STF 62247,
AKOS002382987,
CS-5950,
MCULE-7208913184,
STF-62247/STF62247,
NCGC00344081-02,
NCGC00344081-04,
AK279848,
AN-16819,
HY-100746,
RT-011347,
FT-0719423,
N-(m-tolyl)-4-(4-pyridyl)thiazol-2-amine,
SW220203-1,
EC-000.2320,
J3.666.560B,
STF-62247, >=98% (HPLC), solid,
(4-Pyridin-4-yl-thiazol-2-yl)-m-tolyl-amine,
J-018470,
SR-01000477178-1,
SR-01000477178-3,
N-(3-Methylphenyl)-4-(4-pyridinyl)-1,3-thiazol-2-amine,
D01CIN,
C15H13N3S,
CID704473,
MFCD01121974,
B2151,
A10866,
N-(3-Methylphenyl)-4-(4-pyridinyl)-2-thiazolamine,
Renal cell carcinoma therapy, Stanford University,